Another hot buyout rumor, this time on the heels of today's key patent news for small cap company, NewCardio (NWCI.OB).
Newcardio, Inc.
1.60 +0.50 (+45.45%)
Intraday | 3 Month | 6 Month | 1 Year
Quotes delayed at least 20 mins.
This Silicon Valley based company with a very small share float that wanted to meet with us for a one-on-one interview session at the OneMedForum conference in San Francico. Suddenly, they dropped off the face of the earth and no one could be reached for any comments.
Why?
Rumors began to fly that they were in negotiations for a buy out. After chasing the story for the last 24 hours, it is my opinion that if the "buyout" occurs, it could send shares of this company north of $10.
Company has a brilliant technology that is shaping up to be not only the next great diagnostics tool in cardiovascular medcine, but could also turn into "the ultimate medical phone app." We're talking about a hardward/software combo that would allow anyone to hold their smart phone up to their chest in order to interpret/communicate the readings directly to a doctor.
Designers of this technology have figured out that 90% of doctors don't know how to interpret heart monitor signals correctly and that the technology is "under utilized" as a dignostics tool.
This morning, they announced news about a key patent (which needed to be in place before the rumored sale) and the stock is flying because it has such a low float. If the rumors of the buy-out are true, then shares could easily continue to climb from this morning's trading levels. Day traders were in and out of this stock today based on the news release, but our readers now know something they didn't know when they took profits towards the end of the day.
NewCardio is now entering the commercial phase as a cardiac diagnostic and services company. Their proprietary software platform technologies provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's three-dimensional ECG software platform reduces the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. NewCardio's software products and services significantly improve the diagnosis and monitoring of cardiovascular disease, as well as cardiac safety assessment of drugs under development.
The video below is from the OneMedForum presentation which took place just days ago. More videos and presentations can be found on the company's website:
